Welcome to our dedicated page for Sionna Therapeutics SEC filings (Ticker: SION), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Sionna Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Sionna Therapeutics's regulatory disclosures and financial reporting.
Sionna Therapeutics, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 17, 2026 at 12:00 p.m. Eastern Time. Stockholders will elect four class II directors to serve until 2029 and ratify Deloitte & Touche LLP as independent auditor for 2026.
Stockholders of record at the close of business on April 21, 2026, when 45,142,330 common shares were outstanding and entitled to vote, may participate. The company is using the SEC “Notice and Access” process, providing proxy materials online and offering Internet, telephone, mail, and in‑meeting voting options.
Sionna Therapeutics director-affiliated entity sells SION shares under 10b5-1 plan
Entities associated with director Peter A. Thompson reported open-market sales of a total of 55,345 shares of Sionna Therapeutics common stock at prices around $44.5 per share over two days. The transactions were executed pursuant to a Rule 10b5-1 trading plan, indicating they were pre-arranged.
The shares are held of record by OrbiMed Private Investments VIII, LP, with OrbiMed Capital GP VIII LLC and OrbiMed Advisors LLC potentially deemed to share voting and investment power. After these sales, OrbiMed’s reported indirect holdings stand at 2,964,774 shares of Sionna Therapeutics common stock, and all reporting parties expressly disclaim beneficial ownership beyond any pecuniary interest.
OrbiMed-affiliated funds reported open-market sales of Sionna Therapeutics, Inc. common stock. OrbiMed-related entities sold 52,397 shares on April 17 at $44.68 per share and 2,948 shares on April 18 at $44.52 per share, under a pre-arranged Rule 10b5-1 trading plan. After these indirect transactions through OrbiMed Private Investments VIII, LP, the reporting entities continued to hold 2,964,774 shares of Sionna Therapeutics common stock.
OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC filed an amended ownership report on Sionna Therapeutics, Inc. They report shared voting and dispositive power over 2,967,722 shares of common stock, representing 6.6% of Sionna’s 44,998,073 outstanding shares as stated in the company’s recent annual report.
The filing notes that this amendment reflects a decrease of more than 1% in beneficial ownership following recent sales by OrbiMed Private Investments VIII, L.P. The OrbiMed entities manage these holdings through their investment structures and retain discretion over voting and disposition of the shares.
Sionna Therapeutics, Inc. director Peter A. Thompson reported indirect open-market sales of a total of 510,583 shares of common stock in three transactions. The shares were sold at prices between $44.51 and $45.34 per share pursuant to a Rule 10b5-1 trading plan.
The securities are held of record by OrbiMed Private Investments VIII, LP, an investment fund advised by OrbiMed entities with which Thompson is affiliated. Following these transactions, 3,020,119 shares of common stock remain indirectly held, reflecting a continuing sizable position.
OrbiMed-affiliated funds reported open-market sales of Sionna Therapeutics, Inc. common stock. OrbiMed entities sold a total of 510,583 shares over three days at prices between $44.51 and $45.34 per share under a pre-arranged Rule 10b5-1 trading plan, and continued to hold 3,020,119 shares indirectly after the latest transaction.
The shares are held of record by OrbiMed Private Investments VIII, LP, with OrbiMed Capital GP VIII LLC and OrbiMed Advisors LLC potentially deemed beneficial owners through their control relationships, subject to customary pecuniary-interest and beneficial-ownership disclaimers.
Sionna Therapeutics, Inc. Chief Legal Officer Jennifer Fitzpatrick reported an option exercise and share sale. On March 5, 2026, she exercised a non-qualified stock option for 10,250 shares of common stock at $6.11 per share and immediately sold the same number of shares in an open-market transaction at a weighted average price of $33.8555 per share.
The sale was automatically executed under a Rule 10b5-1 trading plan adopted on June 5, 2025. The shares were sold in multiple trades at prices ranging from $32.56 to $34.83. Following these transactions, she reported 50,935 option shares remaining from this grant and no directly held common shares from this transaction.
Sionna Therapeutics, Inc. registered up to $250,000,000 of common stock for sale under an at-the-market sales agreement with Leerink Partners dated March 2, 2026.
The shelf prospectus is an automatic Form S-3 registration that permits one or more offerings of common stock, preferred stock, debt securities, warrants and units; specific terms will be provided in prospectus supplements. The sales agreement permits ongoing sales from time to time after effectiveness and Leerink may earn up to 3.0% commission on gross sales.
Sionna Therapeutics, Inc. filed its Annual Report describing its strategy as a clinical-stage biopharmaceutical company focused on cystic fibrosis (CF). The company aims to “normalize” CFTR protein function by directly stabilizing nucleotide binding domain 1 (NBD1), long viewed as an undruggable but critical domain affected by the common F508del mutation.
Sionna’s pipeline centers on two NBD1 stabilizers, SION-719 and SION-451, and several complementary CFTR modulators designed for use in proprietary combinations or as add-ons to current standard-of-care regimens such as Trikafta. SION-719 is in a Phase 2a proof-of-concept CF trial as an add-on to Trikafta, after Phase 1 data in healthy volunteers showed it was generally well tolerated with pharmacokinetics supportive of twice-daily dosing.
SION-451 has completed a single-agent Phase 1 study, also showing generally favorable safety and exposure consistent with twice-daily dosing, and is now being tested in dual combinations with correctors SION-2222 and SION-109 in a Phase 1 trial. Earlier AbbVie- and Galapagos-run studies of SION-2222 and potentiator SION-3067 demonstrated improvements in sweat chloride and lung function when used together.
The report emphasizes Sionna’s translational approach using a cystic fibrosis human bronchial epithelial (CFHBE) model, which the company notes has closely tracked clinical outcomes for approved CFTR modulators. Preclinical data suggest that combining Sionna’s NBD1 stabilizers with complementary modulators or Trikafta can raise CFTR activity to near wild-type levels in vitro, which the company believes could translate into clinically meaningful improvements in sweat chloride and lung function for patients who remain inadequately served by existing therapies.